葉酸代謝のバイオマーカーと中国の高齢者の認知障害との関連:横断的な研究
1Department of Geriatrics, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
Frontiers in medicine
|September 3, 2025
まとめ
ビタミンB2,S-アデノシルメチオニン,ホモシステインなどの葉酸代謝バイオマーカーは,中国人の高齢者の認知障害と関連しています. これらの発見は,年齢関連の認知障害の新たなバイオマーカーの可能性を示唆しています.
科学分野:
- ゲロントロジー
- 栄養神経科学
- バイオマーカーの発見
背景:
- 年齢関連の認知障害 (ARCI) は懸念が高まっていますが,葉酸代謝のバイオマーカーの役割は不明です.
- これらのバイオマーカーの理解は 認知能力の低下を特定し 緩和するために不可欠です
研究 の 目的:
- 葉酸代謝に関連するバイオマーカープロファイルと中国の高齢者の認知能力との関連を調査する.
- 年齢関連の認知障害の潜在的バイオマーカーを特定する.
主な方法:
- MMSEとMoCAのスコアを使用して認知状態を分類した100人の参加者を分析した横断的な研究です.
- 葉酸代謝バイオマーカーの血清濃度が測定され,認知機能障害と正常なグループ間で比較されました.
- ロジスティックおよび複数の線形回帰分析では,共変数調整により,バイオマーカーと認知スコアとの関連が検討された.
主要な成果:
- 認知障害が多かった (56. 3%). ビタミンB2 (VB2) と葉酸 (VB9) が低く,S- アデノシルホモシステイン (SAH) とホモシステイン (Hcy) が高かった.
- 認知スコア (MMSE,MoCA) はVB2,VB9,S- アデノシルメチオニン (SAM) と正の相関関係があり,Hcyと負の相関関係がある.
- 教育と血清のHcyは認知障害の有意な予測因子であり,VB2,SAM,Hcyは認知スコアの有意な差異を説明した.
結論:
- ビタミンB2 (VB2),S-アデノシルメチオニン (SAM),ホモシステイン (Hcy) は,中国人の高齢者の認知障害との潜在的な関連を示しています.
- これらのバイオマーカーは,高齢化による認知機能低下における役割と,臨床応用の可能性について,さらなる調査が必要である.
関連する概念動画
01:15Drug Dosing: Geriatric Patients
395
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
395
01:22Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
861
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
861
01:00Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
382
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
382
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
400
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
400
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
354
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
354
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
367
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
367